Hereditary Hemorrhagic Telangiectasia: Genetics, Pathophysiology, Diagnosis, and Management

Adrian Viteri-Noël, Andrés González-García, José Luis Patier, Martin Fabregate, Nuria Bara-Ledesma, Mónica López-Rodríguez, Vicente Gómez Del Olmo, Luis Manzano, Adrian Viteri-Noël, Andrés González-García, José Luis Patier, Martin Fabregate, Nuria Bara-Ledesma, Mónica López-Rodríguez, Vicente Gómez Del Olmo, Luis Manzano

Abstract

Hereditary hemorrhagic telangiectasia is an inherited disease related to an alteration in angiogenesis, manifesting as cutaneous telangiectasias and epistaxis. As complications, it presents vascular malformations in organs such as the lung, liver, digestive tract, and brain. Currently, diagnosis can be made using the Curaçao criteria or by identifying the affected gene. In recent years, there has been an advance in the understanding of the pathophysiology of the disease, which has allowed the use of new therapeutic strategies to improve the quality of life of patients. This article reviews some of the main and most current evidence on the pathophysiology, clinical manifestations, diagnostic approach, screening for complications, and therapeutic options, both pharmacological and surgical.

Keywords: VEGF; angiogenesis; arteriovenous malformations; epistaxis; hereditary hemorrhagic telangiectasias; telangiectasias.

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Main pathways involved in the pathophysiology of HHT. Members of the TGF-β family (mainly BMP9 and 10), bind to specific cell surface type I (R-I) and type II (R-II) receptors. These receptors exhibit serine/threonine kinase activity. The main R-I receptors involved in this pathway are ALK-1 and ALK-5. On the other hand, R-II receptors include TβRII, ActRII, BMPRII. Endoglin is an auxiliary receptor that associates with the ligand, ALK-1/R-II complex, potentiating its action. A soluble form of endoglin (sol-eng) can be generated by proteolysis of the membrane-bound receptor that can sequester ligands (BMP9 or 10) and thus modulate their binding to R-I/R-II receptors. The association between R-I (either ALK-1 or ALK-5) with R-II determines the specificity of ligand signaling. Upon ligand binding, R-II transphosphorylates R-I, which then propagates the signal by phosphorylating the receptor-regulated Smad family of proteins. Once phosphorylated, R-Smads form heteromeric complexes with a cooperating homologue called Co-Smad (Smad4) and translocate to the nucleus where they regulate the transcriptional activity of target genes. In endothelial cells, ALK1 and ALK5 activate signaling two different pathways via Smad1, 5, 8 (ALK1) or Smad2, 3 (ALK5), respectively. The first one promotes transcription of genes related to angiogenesis. The second promotes transcription of genes related to repairing phase. Endoglin, ALK1, Smad4, and BMP9 proteins are encoded by ENG, ACVRL1, MADH4, and GDF2 genes respectively. ActR, activin receptor; BMP, bone morphogenetic protein; BMPR, BMP receptor [14,15,16].
Figure 2
Figure 2
Pulmonary AVMs. AngioCT reconstruction of the thorax of a patient with HHT from the systemic and minority disease unit of the Hospital Ramón y Cajal, with the patient’s consent. Note the AVM located in the left lower lobe (red arrows).

References

    1. Federación Española de Enfermedades Raras. [(accessed on 6 January 2022)]. Available online: .
    1. Sutton H. Epistaxis as an indication of impaired nutrition and of degeneration of the vascular system. Med. Mirror. 1864;1:769–781.
    1. Rendu H. Épistaxis répétées chez un sujet porteur de petits angiomes cutanés et muqueux. Bull. Mem. Soc. Med. Hop. 1896;13:731–733.
    1. Shovlin C.L. Hereditary Haemorrhagic Telangiectasia: Pathophysiology, Diagnosis and Treatment. Blood Rev. 2010;24:203–219. doi: 10.1016/j.blre.2010.07.001.
    1. Zarrabeitia R., Fariñas-Álvarez C., Santibáñez M., Señaris B., Fontalba A., Botella L.M., Parra J.A. Quality of Life in Patients with Hereditary Haemorrhagic Telangiectasia (HHT) Health Qual. Life Outcomes. 2017;15:19. doi: 10.1186/s12955-017-0586-z.
    1. Meier N.M., Foster M.L., Battaile J.T. Hereditary Hemorrhagic Telangiectasia and Pulmonary Arteriovenous Malformations: Clinical Aspects. Cardiovasc. Diagn. Ther. 2018;8:316–324. doi: 10.21037/cdt.2017.12.07.
    1. McDonald J., Stevenson D.A. Hereditary Hemorrhagic Telangiectasia. In: Adam M.P., Mirzaa G.M., Pagon R.A., Wallace S.E., Bean L.J., Gripp K.W., Amemiya A., editors. GeneReviews®. University of Washington; Seattle, WA, USA: 1993.
    1. Olivieri C., Pagella F., Semino L., Lanzarini L., Valacca C., Pilotto A., Corno S., Scappaticci S., Manfredi G., Buscarini E., et al. Analysis of ENG and ACVRL1 Genes in 137 HHT Italian Families Identifies 76 Different Mutations (24 Novel). Comparison with Other European Studies. J. Hum. Genet. 2007;52:820–829. doi: 10.1007/s10038-007-0187-5.
    1. Hernandez F., Huether R., Carter L., Johnston T., Thompson J., Gossage J.R., Chao E., Elliott A.M. Mutations in RASA1 and GDF2 Identified in Patients with Clinical Features of Hereditary Hemorrhagic Telangiectasia. Hum. Genome. Var. 2015;2:15040. doi: 10.1038/hgv.2015.40.
    1. Woodderchack-Donahue W.L., McDonald J., O’Fallon B., Upton P.D., Li W., Romqn B.L., Young S., Plqnt P., Fülöp G.T., Langa C., et al. BMP9 Mutations Cause a Vascular-Anomaly Syndrome with Phenotypic Overlap with Hereditary Hemorrhagic Telangiectasia. Am. J. Hum. Genet. 2013;93:530–537. doi: 10.1016/j.ajhg.2013.07.004.
    1. Goumans M.J., Valdimarsdottir G., Itoh S., Rosendahl A., Sideras P., ten Dijke P. Balancing the Activation State of the Endothelium via Two Distinct TGF-Beta Type I Receptors. EMBO J. 2002;21:1743–1753. doi: 10.1093/emboj/21.7.1743.
    1. Weiss A., Attisano L. The TGFbeta Superfamily Signaling Pathway: TGFbeta Superfamily Signaling Pathway. WIREs Dev. Biol. 2013;2:47–63. doi: 10.1002/wdev.86.
    1. Fernandez-L A., Sanz-Rodriguez F., Blanco F.J., Bernabeu C., Botella L.M. Hereditary Hemorrhagic Telangiectasia, a Vascular Dysplasia Affecting the TGF- Signaling Pathway. Clin. Med. Res. 2006;4:66–78. doi: 10.3121/cmr.4.1.66.
    1. Goumans M.J., Lebrin F., Valdimarsdottir G. Controlling the Angiogenic Switch: A Balance between Two Distinct TGF-b Receptor Signaling Pathways. Trends Cardiovasc. Med. 2003;13:301–307. doi: 10.1016/S1050-1738(03)00142-7.
    1. Cymerman U., Vera S., Pece-Barbara N., Bourdeau A., White R.I., Dunn J., Letarte M. Identification of Hereditary Hemorrhagic Telangiectasia Type 1 in Newborns by Protein Expression and Mutation Analysis of Endoglin. Pediatr. Res. 2000;47:24. doi: 10.1203/00006450-200001000-00008.
    1. Bernabéu C., Blanco F.J., Langa C., Garrido-Martin E.M., Botella L.M. Involvement of the TGF-β Superfamily Signaling Pathway in Hereditary Haemorrhagic Telangiectasia. J. Appl. Biomed. 2010;8:169–177. doi: 10.2478/v10136-009-0020-x.
    1. Letteboer T.G.W., Zewald R.A., Kamping E.J., de Haas G., Mager J.J., Snijder R.J., Lindhout D., Hennekam F.A.M., Westermann C.J.J., Ploos van Amstel J.K. Hereditary Hemorrhagic Telangiectasia: ENG and ALK-1 Mutations in Dutch Patients. Hum. Genet. 2005;116:8–16. doi: 10.1007/s00439-004-1196-5.
    1. Abdalla S.A. Analysis of ALK-1 and Endoglin in Newborns from Families with Hereditary Hemorrhagic Telangiectasia Type 2. Hum. Mol. Genet. 2000;9:1227–1237. doi: 10.1093/hmg/9.8.1227.
    1. Lebrin F., Goumans M.J., Jonker L., Carvalho R.L.C., Valdimarsdottir G., Thorikay M., Mummery C., Arthur H.M., Dijke P. ten Endoglin Promotes Endothelial Cell Proliferation and TGF-β/ALK1 Signal Transduction. EMBO J. 2004;23:4018–4028. doi: 10.1038/sj.emboj.7600386.
    1. Tual-Chalot S., Oh S.P., Arthur H.M. Mouse Models of Hereditary Hemorrhagic Telangiectasia: Recent Advances and Future Challenges. Front. Genet. 2015;6:25. doi: 10.3389/fgene.2015.00025.
    1. Mallet C., Lamribet K., Giraud S., Dupuis-Girod S., Feige J.-J., Bailly S., Tillet E. Functional Analysis of Endoglin Mutations from Hereditary Hemorrhagic Telangiectasia Type 1 Patients Reveals Different Mechanisms for Endoglin Loss of Function. Hum. Mol. Genet. 2015;24:1142–1154. doi: 10.1093/hmg/ddu531.
    1. Snellings D.A., Gallione C.J., Clark D.S., Vozoris N.T., Faughnan M.E., Marchuk D.A. Somatic Mutations in Vascular Malformations of Hereditary Hemorrhagic Telangiectasia Result in Bi-Allelic Loss of ENG or ACVRL1. Am. J. Hum. Genet. 2019;105:894–906. doi: 10.1016/j.ajhg.2019.09.010.
    1. Baysal M., Demir S., Ümit E.G., Gürkan H., Baş V., Karaman Gülsaran S., Demirci U., Kırkızlar H.O., Demir A.M. Two Novel ENG Pathogenic Variations and Genotype-Phenotype Correlations in Hereditary Hemorrhagic Telangiectasia Patients. Balkan Med. J. 2020;37:43–46. doi: 10.4274/balkanmedj.galenos.2019.2019.7.2.
    1. Bernabeu C., Bayrak-Toydemir P., McDonald J., Letarte M. Potential Second-Hits in Hereditary Hemorrhagic Telangiectasia. J. Clin. Med. 2020;9:3571. doi: 10.3390/jcm9113571.
    1. Karlsson T., Cherif H. Mutations in the ENG, ACVRL1, and SMAD4 Genes and Clinical Manifestations of Hereditary Haemorrhagic Telangiectasia: Experience from the Center for Osler’s Disease, Uppsala University Hospital. Upsala J. Med. Sci. 2018;123:153–157. doi: 10.1080/03009734.2018.1483452.
    1. Akhurst R.J., Hata A. Targeting the TGFβ Signalling Pathway in Disease. Nat. Rev. Drug Discov. 2012;11:790–811. doi: 10.1038/nrd3810.
    1. Rossi E., Lopez-Novoa J.M., Bernabeu C. Endoglin Involvement in Integrin-Mediated Cell Adhesion as a Putative Pathogenic Mechanism in Hereditary Hemorrhagic Telangiectasia Type 1 (HHT1) Front. Genet. 2015;5:457. doi: 10.3389/fgene.2014.00457.
    1. Peter M.R., Jerkic M., Sotov V., Douda D.N., Ardelean D.S., Ghamami N., Lakschevitz F., Khan M.A., Robertson S.J., Glogauer M., et al. Impaired Resolution of Inflammation in the Endoglin Heterozygous Mouse Model of Chronic Colitis. Mediat. Inflamm. 2014;2014:767185. doi: 10.1155/2014/767185.
    1. Pérez García M.L. Ph.D. Thesis. University of Salamanca; Salamanca, Spain: 2017. Actualización Clínica y Molecular de la Telangiectasia Hemorrágica Hereditaria en Salamanca.
    1. Meurer S.K., Weiskirchen R. Endoglin: An ‘Accessory’ Receptor Regulating Blood Cell Development and Inflammation. Int. J. Mol. Sci. 2020;21:9247. doi: 10.3390/ijms21239247.
    1. Shovlin C.L., Sulaiman N.L., Govani F.S., Jackson J.E., Begbie M.E. Elevated Factor VIII in Hereditary Haemorrhagic Telangiectasia (HHT): Association with Venous Thromboembolism. Thromb. Haemost. 2007;98:1031–1039.
    1. Rossi E., Pericacho M., Bachelot-Loza C., Pidard D., Gaussem P., Poirault-Chassac S., Blanco F.J., Langa C., González-Manchón C., Novoa J.M.L., et al. Human Endoglin as a Potential New Partner Involved in Platelet–Endothelium Interactions. Cell. Mol. Life Sci. 2018;75:1269–1284. doi: 10.1007/s00018-017-2694-7.
    1. Sánchez-Martínez R., Iriarte A., Mora-Luján J.M., Patier J.L., López-Wolf D., Ojeda A., Torralba M.A., Juyol M.C., Gil R., Añón S., et al. Current HHT Genetic Overview in Spain and Its Phenotypic Correlation: Data from RiHHTa Registry. Orphanet J. Rare Dis. 2020;15:138. doi: 10.1186/s13023-020-01422-8.
    1. Faughnan M.E., Mager J.J., Hetts S.W., Palda V.A., Lang-Robertson K., Buscarini E., Deslandres E., Kasthuri R.S., Lausman A., Poetker D., et al. Second International Guidelines for the Diagnosis and Management of Hereditary Hemorrhagic Telangiectasia. Ann. Intern. Med. 2020;173:989–1001. doi: 10.7326/M20-1443.
    1. McDonald J., Wooderchak-Donahue W., VanSant Webb C., Whitehead K., Stevenson D.A., Bayrak-Toydemir P. Hereditary Hemorrhagic Telangiectasia: Genetics and Molecular Diagnostics in a New Era. Front. Genet. 2015;6:1. doi: 10.3389/fgene.2015.00001.
    1. Leung A.K.C., Leong K.F., Barankin B. Hereditary Hemorrhagic Telangiectasia. J. Pediatr. 2019;210:232. doi: 10.1016/j.jpeds.2019.03.013.
    1. Albiñana V., Cuesta A.M., de Rojas-P I., Gallardo-Vara E., Recio-Poveda L., Bernabéu C., Botella L.M. Review of Pharmacological Strategies with Repurposed Drugs for Hereditary Hemorrhagic Telangiectasia Related Bleeding. J. Clin. Med. 2020;9:1766. doi: 10.3390/jcm9061766.
    1. Cottin V., Plauchu H., Bayle J.-Y., Barthelet M., Revel D., Cordier J.-F. Pulmonary Arteriovenous Malformations in Patients with Hereditary Hemorrhagic Telangiectasia. Am. J. Respir. Crit. Care Med. 2004;169:994–1000. doi: 10.1164/rccm.200310-1441OC.
    1. Khalid S., Garcia-Tsao G. Hepatic Vascular Malformations in Hereditary Hemorrhagic Telangiectasia. Semin. Liver Dis. 2008;28:247–258. doi: 10.1055/s-0028-1085093.
    1. Canzonieri C., Centenara L., Ornati F., Pagella F., Matti E., Alvisi C., Danesino C., Perego M., Olivieri C. Endoscopic Evaluation of Gastrointestinal Tract in Patients with Hereditary Hemorrhagic Telangiectasia and Correlation with Their Genotypes. Genet. Med. 2014;16:3–10. doi: 10.1038/gim.2013.62.
    1. Eker O.F., Boccardi E., Sure U., Patel M.C., Alicante S., Alsafi A., Coote N., Droege F., Dupuis O., Fialla A.D., et al. European Reference Network for Rare Vascular Diseases (VASCERN) Position Statement on Cerebral Screening in Adults and Children with Hereditary Haemorrhagic Telangiectasia (HHT) Orphanet J. Rare Dis. 2020;15:165. doi: 10.1186/s13023-020-01386-9.
    1. Parambil J.G. Hereditary Hemorrhagic Telangiectasia. Clin. Chest Med. 2016;37:513–521. doi: 10.1016/j.ccm.2016.04.013.
    1. Galiè N., Humbert M., Vachiery J.-L., Gibbs S., Lang I., Torbicki A., Simonneau G., Peacock A., Vonk Noordegraaf A., Beghetti M., et al. 2015 ESC/ERS Guidelines for the Diagnosis and Treatment of Pulmonary Hypertension: The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS)Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT) Eur. Heart J. 2016;37:67–119. doi: 10.1093/eurheartj/ehv317.
    1. Shovlin C.L., Guttmacher A.E., Buscarini E., Faughnan M.E., Hyland R.H., Westermann C.J.J., Kjeldsen A.D., Plauchu H. Diagnostic Criteria for Hereditary Hemorrhagic Telangiectasia (Rendu-Osler-Weber Syndrome) Am. J. Med. Genet. 2000;91:66–67. doi: 10.1002/(SICI)1096-8628(20000306)91:1<66::AID-AJMG12>;2-P.
    1. Velthuis S., Buscarini E., van Gent M.W.F., Gazzaniga P., Manfredi G., Danesino C., Schonewille W.J., Westermann C.J.J., Snijder R.J., Mager J.J., et al. Grade of Pulmonary Right-to-Left Shunt on Contrast Echocardiography and Cerebral Complications. Chest. 2013;144:542–548. doi: 10.1378/chest.12-1599.
    1. Saboo S.S., Chamarthy M., Bhalla S., Park H., Sutphin P., Kay F., Battaile J., Kalva S.P. Pulmonary Arteriovenous Malformations: Diagnosis. Cardiovasc. Diagn. Ther. 2018;8:325–337. doi: 10.21037/cdt.2018.06.01.
    1. Majumdar S., McWilliams J.P. Approach to Pulmonary Arteriovenous Malformations: A Comprehensive Update. J. Clin. Med. 2020;9:1927. doi: 10.3390/jcm9061927.
    1. Brenard R., Chapaux X., Deltenre P., Henrion J., De Maeght S., Horsmans Y., Borbath I., Leenaerts A., Van Cauter J., Francque S., et al. Large Spectrum of Liver Vascular Lesions Including High Prevalence of Focal Nodular Hyperplasia in Patients with Hereditary Haemorrhagic Telangiectasia: The Belgian Registry Based on 30 Patients: Eur. J. Gastroenterol. Hepatol. 2010;22:1253–1259. doi: 10.1097/MEG.0b013e32833ac4a1.
    1. de Gussem E.M., Kroon S., Hosman A.E., Kelder J.C., Post M.C., Snijder R.J., Mager J.J. Hereditary Hemorrhagic Telangiectasia (HHT) and Survival: The Importance of Systematic Screening and Treatment in HHT Centers of Excellence. J. Clin. Med. 2020;9:3581. doi: 10.3390/jcm9113581.
    1. Al-Samkari H. Hereditary Hemorrhagic Telangiectasia: Systemic Therapies, Guidelines, and an Evolving Standard of Care. Blood. 2021;137:888–895. doi: 10.1182/blood.2020008739.
    1. Gaillard S., Dupuis-Girod S., Boutitie F., Rivière S., Morinière S., Hatron P.-Y., Manfredi G., Kaminsky P., Capitaine A.-L., Roy P., et al. Tranexamic Acid for Epistaxis in Hereditary Hemorrhagic Telangiectasia Patients: A European Cross-over Controlled Trial in a Rare Disease. J. Thromb. Haemost. 2014;12:1494–1502. doi: 10.1111/jth.12654.
    1. Geisthoff U.W., Seyfert U.T., Kübler M., Bieg B., Plinkert P.K., König J. Treatment of Epistaxis in Hereditary Hemorrhagic Telangiectasia with Tranexamic Acid—A Double-Blind Placebo-Controlled Cross-over Phase IIIB Study. Thromb. Res. 2014;134:565–571. doi: 10.1016/j.thromres.2014.06.012.
    1. Whitehead K.J., Sautter N.B., McWilliams J.P., Chakinala M.M., Merlo C.A., Johnson M.H., James M., Everett E.M., Clancy M.S., Faughnan M.E., et al. Effect of Topical Intranasal Therapy on Epistaxis Frequency in Patients with Hereditary Hemorrhagic Telangiectasia: A Randomized Clinical Trial. JAMA. 2016;316:943. doi: 10.1001/jama.2016.11724.
    1. Baysal M., Ümit E., Kırkızlar H.O., Özdöver A.C., Demir A.M. Thalidomide for the Management of Bleeding Episodes in Patients with Hereditary Hemorrhagic Telangiectasia: Effects on Epistaxis Severity Score and Quality of Life. Turk. J. Hematol. 2019;36:43–47. doi: 10.4274/tjh.galenos.2018.2018.0190.
    1. Invernizzi R., Quaglia F., Klersy C., Pagella F., Ornati F., Chu F., Matti E., Spinozzi G., Plumitallo S., Grignani P., et al. Efficacy and Safety of Thalidomide for the Treatment of Severe Recurrent Epistaxis in Hereditary Haemorrhagic Telangiectasia: Results of a Non-Randomised, Single-Centre, Phase 2 Study. Lancet Haematol. 2015;2:e465–e473. doi: 10.1016/S2352-3026(15)00195-7.
    1. Unity Health Toronto Tacrolimus Trial for Hereditary Hemorrhagic Telangiectasia (HHT) 2022. [(accessed on 20 June 2022)]; Available online: .
    1. Wirsching K.E.C., Kühnel T.S. Update on Clinical Strategies in Hereditary Hemorrhagic Telangiectasia from an ENT Point of View. Clin. Exp. Otorhinolaryngol. 2017;10:153–157. doi: 10.21053/ceo.2016.00318.
    1. Werner J.A., Lippert B.M., Geisthoff U.W., Rudert H. Nd:YAG-Lasertherapie der rezidivierenden Epistaxis bei hereditärer hämorrhagischer Teleangiektasie. Laryngo-Rhino-Otologie. 1997;76:495–501. doi: 10.1055/s-2007-997467.
    1. Esteban-Casado S., Martín de Rosales Cabrera A.M., Usarralde Pérez A., Martínez Simón J.J., Zhan Zhou E., Marcos Salazar M.S., Pérez Encinas M., Botella Cubells L. Sclerotherapy and Topical Nasal Propranolol: An Effective and Safe Therapy for HHT-Epistaxis. Laryngoscope. 2019;129:2216–2223. doi: 10.1002/lary.27930.
    1. Marcos S., Botella L.M., Albiñana V., Arbia A., de Rosales A.M. Sclerotherapy on Demand with Polidocanol to Treat HHT Nosebleeds. J. Clin. Med. 2021;10:3845. doi: 10.3390/jcm10173845.
    1. Luk L., Mace J.C., Bhandarkar N.D., Sautter N.B. Comparison of Electrosurgical Plasma Coagulation and Potassium-Titanyl-Phosphate Laser Photocoagulation for Treatment of Hereditary Hemorrhagic Telangiectasia-Related Epistaxis: Comparison of EPC and KPT Treatment for HHT. Int. Forum Allergy Rhinol. 2014;4:640–645. doi: 10.1002/alr.21328.
    1. Harvey R.J., Kanagalingam J., Lund V.J. The Impact of Septodermoplasty and Potassium-Titanyl-Phosphate (KTP) Laser Therapy in the Treatment of Hereditary Hemorrhagic Telangiectasia-Related Epistaxis. Am. J. Rhinol. 2008;22:182–187. doi: 10.2500/ajr.2008.22.3145.
    1. Richer S.L., Geisthoff U.W., Livada N., Ward P.D., Johnson L., Mainka A., Henderson K.J., Maune S., White R.I., Ross D.A. The Young’s Procedure for Severe Epistaxis from Hereditary Hemorrhagic Telangiectasia. Am. J. Rhinol. Allergy. 2012;26:401–404. doi: 10.2500/ajra.2012.26.3809.
    1. Tellapuri S., Park H.S., Kalva S.P. Pulmonary Arteriovenous Malformations. Int. J. Cardiovasc. Imaging. 2019;35:1421–1428. doi: 10.1007/s10554-018-1479-x.
    1. van Gent M.W.F., Post M.C., Luermans J.G.L.M., Snijder R.J., Westermann C.J.J., Plokker H.W.M., Overtoom T.T., Mager J.J. Screening for Pulmonary Arteriovenous Malformations Using Transthoracic Contrast Echocardiography: A Prospective Study. Eur. Respir. J. 2009;33:85–91. doi: 10.1183/09031936.00049008.
    1. Swanson E., Mahgoub A., MacDonald R., Shaukat A. Medical and Endoscopic Therapies for Angiodysplasia and Gastric Antral Vascular Ectasia: A Systematic Review. Clin. Gastroenterol. Hepatol. 2014;12:571–582. doi: 10.1016/j.cgh.2013.08.038.
    1. Houghton K.D., Umar B., Schairer J. Successful Treatment of Hereditary Hemorrhagic Telangiectasia with Octreotide. ACG Case Rep. J. 2019;6:e00088. doi: 10.14309/crj.0000000000000088.
    1. University Hospital Bordeaux Study of the Efficacy of Propranolol for the Management of Epistaxis in Hereditary Hemorrhagic Telangiectasia Patients. [(accessed on 22 June 2022)];2022 Available online: .
    1. Buscarini E., Botella L.M., Geisthoff U., Kjeldsen A.D., Mager H.J., Pagella F., Suppressa P., Zarrabeitia R., Dupuis-Girod S., on behalf of VASCERN-HHT et al. Safety of Thalidomide and Bevacizumab in Patients with Hereditary Hemorrhagic Telangiectasia. Orphanet J. Rare Dis. 2019;14:28. doi: 10.1186/s13023-018-0982-4.
    1. Kim Y.H., Kim M.-J., Choe S.-W., Sprecher D., Lee Y.J., Oh S.P. Selective Effects of Oral Antiangiogenic Tyrosine Kinase Inhibitors on an Animal Model of Hereditary Hemorrhagic Telangiectasia. J. Thromb. Haemost. 2017;15:1095–1102. doi: 10.1111/jth.13683.
    1. Faughnan M.E., Gossage J.R., Chakinala M.M., Oh S.P., Kasthuri R., Hughes C.C.W., McWilliams J.P., Parambil J.G., Vozoris N., Donaldson J., et al. Pazopanib may reduce bleeding in hereditary hemorrhagic telangiectasia. Angiogenesis. 2019;22:145–155. doi: 10.1007/s10456-018-9646-1.
    1. McCrae K. A Phase I Single Arm Study to Assess the Safety and Efficacy of Pomalidomide in Patients with Bleeding Due to Hereditary Hemorrhagic Telangiectasia and Refractory Angiodysplasia. [(accessed on 29 August 2022)];2020 Available online: .
    1. Bharatha A., Faughnan M.E., Kim H., Pourmohamad T., Krings T., Bayrak-Toydemir P., Pawlikowska L., McCulloch C.E., Lawton M.T., Dowd C.F., et al. Brain Arteriovenous Malformation Multiplicity Predicts the Diagnosis of Hereditary Hemorrhagic Telangiectasia: Quantitative Assessment. Stroke. 2012;43:72–78. doi: 10.1161/STROKEAHA.111.629865.
    1. Albiñana V., Giménez-Gallego G., García-Mato A., Palacios P., Recio-Poveda L., Cuesta A.-M., Patier J.-L., Botella L.-M. Topically Applied Etamsylate: A New Orphan Drug for HHT-Derived Epistaxis (Antiangiogenesis through FGF Pathway Inhibition) TH Open. 2019;3:e230–e243. doi: 10.1055/s-0039-1693710.
    1. Vaderis Therapeutics AG A Randomised, Placebo Controlled, Double Blind, Multicentre Proof of Concept Study to Assess the Safety and Efficacy of Two Doses of VAD044 in Patients with Hereditary Hemorrhagic Telangiectasia (HHT) [(accessed on 22 June 2022)];2022 Available online: .

Source: PubMed

Sponsors et collaborateurs

Les conditions médicales

Interventions en matière de drogue

3
S'abonner